Read more: To view or add a comment, sign in FDA approves globally first obesity pill FDA approves Novo Nordisks first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence
The recent approval of empagliflozin for children and adolescents with T2D marks a crucial step forward, with initial studies reporting promising results
Houshdaran S, Oke AB, Fung JC, Vo KC, Nezhat C, Giudice LC
First, there is simply no component data supporting indefinite, continuous, year-round use the honest position is that nobody has studied that, so the protocol builds in a stop
The reasons: Receptor sensitivity: While GHK-Cu doesn't appear to cause receptor downregulation the way some peptides do, cycling is a general precaution to maintain responsiveness and avoid adaptations that might blunt benefits
For now, we still stay away